Elliott Investment Management's Marc Steinberg at #JPM24 (Brian Benton Photography)

January 8, 2024 03:48 PM EST

Elliott's Marc Steinberg sees more healthcare investments for the sometimes-activist firm this year: #JPM24

Drew Armstrong

Executive Editor

Andrew Dunn

Senior Biopharma Correspondent

SAN FRANCISCO — After 2023’s set of high-profile activist investments in healthcare, Elliott Investment Management’s Marc Steinberg sees more action this year in the space for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Elliott's Marc Steinberg sees more healthcare investments for the sometimes-activist firm this year: #JPM24

Drew Armstrong

Executive Editor

Andrew Dunn

Senior Biopharma Correspondent

Sign up to read this article for free.

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

FDA vaccine chief Peter Marks pledges to stay as long as he's welcome

Patient dies in Neurogene's Rett syndrome study

Are programs with compounded GLP-1s safe for your population?

El­liot­t's Marc Stein­berg sees more health­care in­vest­ments for the some­times-ac­tivist firm this year: #JPM24

Executive Editor

Senior Biopharma Correspondent

Sign up to read this article for free.

Elliott's Marc Steinberg sees more healthcare investments for the sometimes-activist firm this year: #JPM24